SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened volatility and community speculation, with investors tracking options flow and potential gamma exposure as the stock tests key technical levels. While discussions remain centered on the prospect of a short squeeze and long-term turnaround efforts, the community is actively debating whether upcoming corporate actions or market technicals will act as the catalyst for sustained upward momentum.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors position for a potential short squeeze ahead of its upcoming earnings report, with the community highlighting high borrow rates and limited share availability. Bullish sentiment is being driven by speculation regarding potential partnerships and the strategic value of recent acquisitions, leading retail traders to advocate for holding positions to put pressure on short sellers.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is seeing intense trading activity as investors react to a private placement and a new licensing deal for its anti-IgE asset, leading to speculation about a potential short squeeze. The community remains divided, with some traders targeting significant upside from the company's clinical pipeline, while others warn of volatility and structural risks following a recent reverse stock split.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is trending due to significant volatility and volume, with the community actively debating whether the stock is a prime candidate for a short squeeze or a potential pump-and-dump trap linked to share dilution concerns. Traders are closely watching micro-float dynamics and pivot points as the stock maintains heavy interest from day traders seeking momentum plays.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors weigh significant concerns over executive compensation and financial internal controls against the potential of new international contracts. The community remains divided between skepticism regarding management's communication style and bullish sentiment focused on the company's long-term integration into modern defense procurement.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining attention as traders speculate on potential price action and volatility ahead of the Juneteenth period, a timeframe that has historically triggered significant speculative momentum in the stock. Community discussion is currently centered on these seasonal trends, low float dynamics, and persistent interest in the stock's potential for sudden, volume-driven swings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors digest a massive earnings beat and a newly announced six-billion-dollar share buyback, leading to a surge in bullish analyst price target revisions. While some are treating the stock's recent parabolic rally as a sell-the-news event, the community remains intensely divided between those betting on a sustained AI-driven memory supercycle and those calling for a sharp correction from current highs.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is seeing heightened volatility as investors grapple with conflicting signals from geopolitical tensions and ongoing sector rotation. While small caps exhibit price resilience, market participants are actively debating whether these levels represent sustainable momentum or a precarious build-up before a broader market pivot.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors focus on the company's BLA submission for its lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is actively debating the significance of recent partnership news and management's strategy, with sentiment divided between those anticipating a major revaluation following FDA milestones and those concerned about the company's cash burn and competitive positioning.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending following a strong earnings report and the announcement of a new value menu launching in April, which aims to regain its reputation for affordability amid high consumer sensitivity to prices. Investors are closely monitoring how this strategy impacts traffic and margins, while community sentiment remains divided between those viewing the company as a durable defensive value play and those skeptical of the brand's long-term quality and leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up

(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...

<ul class="summary-bullets"><li>Scynexis signed a definitive agreement to acquire SCY-770, a novel oral therapy to treat Autosomal Dominant Polycystic Kidney Disease.</li><li>The biotech firm will pay $8 million upfront to Poxel and up to another $8 million tied to development milestones.</li><li>The company plans to begin a Phase 2 study of SCY-770 in late 2026.</li></ul>Shares of Scynexis, Inc. (SCYX) gave up most of their early gains but traded around 2% higher in pre-market on Tuesday after the biotech firm announced a deal with Poxel S.A. to acquire a potential treatment for a kidney disease, alongside securing $40 million through a private placement.Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), a leading cause of kidney failure.Under the agreement, Scynexis will pay $8 million upfront and up to another $8 million tied to development milestones. The company could also pay up to $180 million in commercial milestones, including $125 million if annual sales reach $1 billion or more.<h2 class="st-heading-2">Scynexis To Begin Phase 2 Study Of SCY-770 In Late 2026</h2>The company plans to begin a Phase 2 study in late 2026, with early results expected in the second half of 2027. The therapy has also received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).The oral therapy is designed to target the root causes of ADPKD by slowing cyst growth and limiting disease progression.“SCY-770 is supported by a strong pre-clinical data package and a novel differentiated MOA that targets multiple key drivers of ADPKD progression, positioning it as a promising candidate in a significant rare disease market with a high unmet need. Our near-term priority is to efficiently advance SCY-770 into a Phase 2 POC study later this year,” said David Angulo, President and CEO of Scynexis.Separately, Scynexis said it expects to raise about $40 million upfront from the private placement, with the potential to bring in up to an additional $52.2 million if all warrants are exercised for cash.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SCYX">SCYX</a> on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said they want to see the company being bought out.<stembedurl>https://stocktwits.com/ViktorSinclair/message/649025612</stembedurl>Another user said the company should remain focused on the anti-fungal space.<stembedurl>https://stocktwits.com/Varus_q/message/649029010</stembedurl>Pre-market volumes were strong, with 7.8 million shares changing hands, compared with an average of around 0.4 million, according to Stocktwits data.Year-to-date, the stock has gained around 25%.For updates and corrections, email newsroom[at]stocktwits[dot]com

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

  Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market

The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.

Equity

SCYNEXIS Q4 Earnings Assessment

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

SCYX
Scynexis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SCYX News

SCYXScynexis Inc